Nyxoah S.A. (NASDAQ:NYXH – Get Rating) – Cantor Fitzgerald lowered their FY2023 earnings estimates for shares of Nyxoah in a report issued on Thursday, May 18th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($1.66) per share for the year, down from their prior forecast of ($1.29). The consensus estimate for Nyxoah’s current full-year earnings is ($1.80) per share.
Several other research firms have also weighed in on NYXH. Piper Sandler reduced their price objective on shares of Nyxoah from $13.00 to $12.00 in a research note on Wednesday, May 17th. Stifel Nicolaus reduced their price objective on shares of Nyxoah from $16.00 to $15.00 in a research note on Wednesday, May 17th.
Nyxoah Stock Down 3.9 %
Nyxoah (NASDAQ:NYXH – Get Rating) last issued its earnings results on Wednesday, March 22nd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.24). The business had revenue of $1.34 million during the quarter, compared to the consensus estimate of $2.91 million. Nyxoah had a negative net margin of 1,270.87% and a negative return on equity of 28.01%.
Institutional Trading of Nyxoah
Several hedge funds have recently bought and sold shares of the stock. Invesco Ltd. acquired a new stake in Nyxoah during the 1st quarter worth approximately $8,177,000. AXA S.A. raised its holdings in shares of Nyxoah by 1.4% in the first quarter. AXA S.A. now owns 217,000 shares of the company’s stock valued at $1,621,000 after purchasing an additional 3,000 shares during the last quarter. Sio Capital Management LLC raised its holdings in shares of Nyxoah by 1,072.4% in the first quarter. Sio Capital Management LLC now owns 188,875 shares of the company’s stock valued at $1,411,000 after purchasing an additional 172,765 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Nyxoah in the first quarter valued at approximately $965,000. Finally, Sei Investments Co. acquired a new stake in shares of Nyxoah in the second quarter valued at approximately $265,000. 11.47% of the stock is currently owned by institutional investors and hedge funds.
Nyxoah Company Profile
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
- Get a free copy of the StockNews.com research report on Nyxoah (NYXH)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.